CRISPR Therapeutics AG (CRSP) EPS (Weighted Average and Diluted) (2018 - 2026)

CRISPR Therapeutics AG has disclosed EPS (Weighted Average and Diluted) across 9 years of filings, most recently posting -$1.28 for Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at -$1.28, up 18.99% year-over-year; the trailing twelve-month figure through Mar 2026 was -$6.2 (down 37.78% YoY), and the FY2025 annual result was -$6.47, down 49.08% from the prior year.
• EPS (Weighted Average and Diluted) came in at -$1.28 for Q1 2026 at CRISPR Therapeutics AG, up from -$1.35 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.13 in Q4 2023 to a low of -$2.4 in Q2 2022.
• The 5-year median for EPS (Weighted Average and Diluted) is -$1.4 (2022), against an average of -$1.32.
• Across the five-year window, EPS (Weighted Average and Diluted) soared 180.71% in 2023 and plunged 221.43% in 2025, its largest moves.
• CRISPR Therapeutics AG's EPS (Weighted Average and Diluted) stood at -$1.4 in 2022, then jumped by 180.71% to $1.13 in 2023, then plunged by 137.17% to -$0.42 in 2024, then slumped by 221.43% to -$1.35 in 2025, then advanced by 5.19% to -$1.28 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at -$1.28 (Q1 2026), -$1.35 (Q4 2025), and -$1.17 (Q3 2025), per Business Quant data.